Pfizer (PFE.US) Tukysa Amerika Qo‘shma Shtatlari tomonidan birinchi bosqich ko‘krak bezi saratoni davolash uchun ma’qullandi
Pfizer (PFE.US) chorshanba kuni e’lon qildi, AQSh Oziq-ovqat va dori-darmon ma’muriyati (FDA) uning tirozin kinaza inhibitörü Tukysa (tucatinib)ni muayyan ko’krak bezi saratoni uchun birinchi bosqich terapiya sifatida birgalikdagi davolash rejasi doirasida tasdiqlaganini.
JitTong Finance APP xabariga ko‘ra, Pfizer (PFE.US) chorshanba kuni e’lon qildi: AQSH Oziq-ovqat va dori vositalari ma’muriyati (FDA) uning tirozin kinaza inhibitori Tukysa (tucatinib) preparatini ma’lum bir ko‘krak bezi saratoni uchun birinchi bosqichda qo‘llaniladigan kombinatsiyalangan davolashning bir qismi sifatida tasdiqladi.
Ushbu tasdiqlash Tukysa preparatining HER2 musbat (HER2+) ko‘krak bezi saratoni bilan kasallangan kattalar bemorlari uchun, Trastuzumab va Pertuzumab (Roche (RHHBY.US) tomonidan mos ravishda Herceptin va Perjeta nomi ostida sotiladigan ikki xil saraton preparati) yuqumlantiruvchi davolashini olganidan keyin qo‘llanishiga ruxsat beradi.
Qaror Pfizer'ning HER2CLIMB-05 III bosqichli klinik sinov ma’lumotlari bilan qo‘llab-quvvatlandi. Ushbu sinovda, Tukysa Trastuzumab va Pertuzumab bilan birga HER2 musbat metastatik ko‘krak bezi saratoni (MBC) bemorlarida birga ishlatilganda, asosiy nuqta — kasallikning oldinga siljishsiz yashash davrini — qo‘lga kiritdi va xavfsizlik jihatdan ham yaxshi baholandi.
Ushbu og‘iz orqali qabul qilinadigan dori ilgari AQSHda tasdiqlangan bo‘lib, ilgari HER2 musbat, operatsiya qilib bo‘lmaydigan yoki metastatik ko‘krak bezi saratoni bilan og‘rigan kattalar bemorlar uchun qo‘shimcha davolash tanlovi sifatida; kimyoterapiya, kapesitabin va Trastuzumab bilan birga ishlatilishi mumkin.
Pfiizer aksiyalari chorshanba kuni 1.8%ga o‘sdi va yil boshidan buyon jami 18%ga ko‘tarildi.
Mas'uliyatni rad etish: Ushbu maqolaning mazmuni faqat muallifning fikrini aks ettiradi va platformani hech qanday sifatda ifodalamaydi. Ushbu maqola investitsiya qarorlarini qabul qilish uchun ma'lumotnoma sifatida xizmat qilish uchun mo'ljallanmagan.
Sizga ham yoqishi mumkin
Oltin va kumushni arzon narxda sotib olishning asosiy shartlari 261008
SK Hynix Solidigm’ni AQSHga IPO uchun ajratadi: Goldman Sachs va Morgan Stanley yetakchi underwriter, 10 billions dollar AI storagega yo'naltirilgan mablag' yig'ish
SK Hynix o'zining NAND flesh xotira sho'ba kompaniyasi Solidigm uchun AQShda IPO o'tkazish uchun underwriterlar tarkibini aniqladi, va asosiy yetakchilar sifatida Goldman Sachs hamda Morgan Stanley tanlandi, yig'iladigan mablag' taxminan 10 billion dollarga teng. Bu, SK Hynix Intelning NAND va SSD biznesini sotib olib Solidigmni tashkil etganidan beri, ushbu aktiv uchun ilk bor mustaqil kapital operatsiyasi yo'lini aniqlab bermoqda.
Yangilangan versiya 1 - Firmus 50 billions dollar IPO rejasini o‘zgartirishni ko‘rib chiqayotgani haqida xabarlar bor, Avstraliyaning Maas Group aksiyalari 30% ga pasaydi.
Reuters 8 October – On Thursday, reports emerged that the AI company Firmus backed by NVIDIA (NVDA.O) is considering adjusting the terms of its widely anticipated $5 billion IPO, causing Maas Group (MGH.AX) shares in Australia to plunge by up to 30%. The price dropped to 4.47 AUD, marking the biggest daily loss and the lowest point since May 6, evaporating approximately 694 million AUD (483.37 million USD) in market value for the construction services company. Here are additional details: Maas holds a 3.2% stake in the data center operator; earlier in August, it pledged an extra investment of 300 million AUD through common and preferred shares priced at 230 AUD per share. In a statement to the exchange, Maas noted that speculation over whether the IPO will proceed as planned has put pressure on market sentiment, and added that it has no undisclosed information explaining the current trading situation. Firmus lists OpenAI as an anchor client and is preparing the second-largest IPO in Australian history. Earlier this week, reports indicated the company may reduce its offering price from 11 AUD per share. If this IPO succeeds, it will be the largest in Australia in almost thirty years, second only to the Telstra IPO in 1997 (TLS.AX), which was approximately $10 billion. Before Thursday’s sharp drop, Maas Group shares had climbed about 44% in the past 12 months, as investors valued its connection to AI-driven data center construction. Firmus has not responded immediately to Reuters’ request for comment. (1 USD = 1.4358 AUD) For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation and provides it only for readers' convenience. Reuters bears no responsibility for any loss or damage arising from the use of automated translation.
SK Hynix (SKHY.US) ning flash xotira bo‘limi Goldman Sachs va Morgan Stanley boshchiligida 2027 yilda AQSh IPOga chiqish uchun tayyorlanmoqda.
Ma’lumotlarga ko‘ra, SK Hynix (SKHY.US) kompaniyasining flash xotira bo‘limi Solidigm kelgusi yilda AQShda IPO o‘tkazishni rejalashtirmoqda va bosh bank sifatida Goldman Sachs hamda Morgan Stanley tanlandi.
Kripto narxlari
Ko'proq
